IMS 1313-nanoparticle mucosal vaccine enhances immunity against avian influenza and Newcastle disease viruses

Nermeen M. Ismail, Ayman H. El-Deeb, Mohamed Emara, Hoda I. Tawfik, Nabil Abdel Wanis, Hussein A. Hussein

Research output: Contribution to journalArticle

Abstract

Background and Objective: Avian influenza and Newcastle disease viruses are a continuous threat to poultry industry. Vaccines are increasingly used to control these viral infections. This study aimed to develop efficacious vaccines and vaccination strategies against avian influenza and Newcastle disease viruses. Methodology: Two formulations of bivalent vaccines for avian influenza and Newcastle disease viruses were prepared based on the use of IMS1313-nanoparticles (mucosal vaccine) and Montanide ISA71 (parental vaccine) adjuvants. The prepared vaccines were delivered in specific pathogen free (SPF) chickens with different vaccination protocols. Cell mediated and humoral immune response (cytokine expression levels including IFN-γ and IL-6, lymphocyte proliferation, antibodies titers against both H5N1 and NDV) were measured. Challenge trial was carried out to determine the protection percent and shedding pattern of the challenged viruses. Results: Results of the present study revealed a significant increase of IFN-γ and IL-6 genes expression and lymphocytes proliferation in the vaccinated groups compared to the unvaccinated group. Two applications of the mucosal vaccine demonstrated higher hemagglutination inhibition (HI) titers and protection percentage ranged from 40-50% with different levels of virus shedding as measured by qRT-PCR assay. However, when the vaccines were applied in a prime-boost protocol (mucosal-parental, respectively), protection reached 90 and 100% against avian influenza virus (AIV) and Newcastle disease virus (NDV), respectively. No shedding of the NDV-challenge virus was detected whereas, AIV-challenge virus was detected in the samples of the 3rd day post-challenge. Conclusion: Indeed, the use of mucosal-parental vaccines in a prime-boost vaccination protocol demonstrated the potentiality of such approach.

Original languageEnglish
Pages (from-to)167-174
Number of pages8
JournalInternational Journal of Poultry Science
Volume17
Issue number4
DOIs
Publication statusPublished - 1 Jan 2018

Fingerprint

Bird Diseases
Newcastle disease virus
Influenza in Birds
avian influenza
nanoparticles
Nanoparticles
Immunity
Vaccines
immunity
vaccines
vaccination
Vaccination
lymphocyte proliferation
Influenza A virus
interleukin-6
Virus Diseases
viruses
Viruses
Orthomyxoviridae
Interleukin-6

Keywords

  • Avian influenza virus
  • H5N1
  • IMS1313-nanoparticles
  • ISA71
  • NDV genotype VIId
  • Newcastle disease virus
  • Poultry industry

ASJC Scopus subject areas

  • Food Animals
  • Animal Science and Zoology

Cite this

IMS 1313-nanoparticle mucosal vaccine enhances immunity against avian influenza and Newcastle disease viruses. / Ismail, Nermeen M.; El-Deeb, Ayman H.; Emara, Mohamed; Tawfik, Hoda I.; Wanis, Nabil Abdel; Hussein, Hussein A.

In: International Journal of Poultry Science, Vol. 17, No. 4, 01.01.2018, p. 167-174.

Research output: Contribution to journalArticle

Ismail, Nermeen M. ; El-Deeb, Ayman H. ; Emara, Mohamed ; Tawfik, Hoda I. ; Wanis, Nabil Abdel ; Hussein, Hussein A. / IMS 1313-nanoparticle mucosal vaccine enhances immunity against avian influenza and Newcastle disease viruses. In: International Journal of Poultry Science. 2018 ; Vol. 17, No. 4. pp. 167-174.
@article{584f4c1bfaa040579c4e01fbe632faba,
title = "IMS 1313-nanoparticle mucosal vaccine enhances immunity against avian influenza and Newcastle disease viruses",
abstract = "Background and Objective: Avian influenza and Newcastle disease viruses are a continuous threat to poultry industry. Vaccines are increasingly used to control these viral infections. This study aimed to develop efficacious vaccines and vaccination strategies against avian influenza and Newcastle disease viruses. Methodology: Two formulations of bivalent vaccines for avian influenza and Newcastle disease viruses were prepared based on the use of IMS1313-nanoparticles (mucosal vaccine) and Montanide ISA71 (parental vaccine) adjuvants. The prepared vaccines were delivered in specific pathogen free (SPF) chickens with different vaccination protocols. Cell mediated and humoral immune response (cytokine expression levels including IFN-γ and IL-6, lymphocyte proliferation, antibodies titers against both H5N1 and NDV) were measured. Challenge trial was carried out to determine the protection percent and shedding pattern of the challenged viruses. Results: Results of the present study revealed a significant increase of IFN-γ and IL-6 genes expression and lymphocytes proliferation in the vaccinated groups compared to the unvaccinated group. Two applications of the mucosal vaccine demonstrated higher hemagglutination inhibition (HI) titers and protection percentage ranged from 40-50{\%} with different levels of virus shedding as measured by qRT-PCR assay. However, when the vaccines were applied in a prime-boost protocol (mucosal-parental, respectively), protection reached 90 and 100{\%} against avian influenza virus (AIV) and Newcastle disease virus (NDV), respectively. No shedding of the NDV-challenge virus was detected whereas, AIV-challenge virus was detected in the samples of the 3rd day post-challenge. Conclusion: Indeed, the use of mucosal-parental vaccines in a prime-boost vaccination protocol demonstrated the potentiality of such approach.",
keywords = "Avian influenza virus, H5N1, IMS1313-nanoparticles, ISA71, NDV genotype VIId, Newcastle disease virus, Poultry industry",
author = "Ismail, {Nermeen M.} and El-Deeb, {Ayman H.} and Mohamed Emara and Tawfik, {Hoda I.} and Wanis, {Nabil Abdel} and Hussein, {Hussein A.}",
year = "2018",
month = "1",
day = "1",
doi = "10.3923/ijps.2018.167.174",
language = "English",
volume = "17",
pages = "167--174",
journal = "International Journal of Poultry Science",
issn = "1682-8356",
publisher = "Asian Network for Scientific Information",
number = "4",

}

TY - JOUR

T1 - IMS 1313-nanoparticle mucosal vaccine enhances immunity against avian influenza and Newcastle disease viruses

AU - Ismail, Nermeen M.

AU - El-Deeb, Ayman H.

AU - Emara, Mohamed

AU - Tawfik, Hoda I.

AU - Wanis, Nabil Abdel

AU - Hussein, Hussein A.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background and Objective: Avian influenza and Newcastle disease viruses are a continuous threat to poultry industry. Vaccines are increasingly used to control these viral infections. This study aimed to develop efficacious vaccines and vaccination strategies against avian influenza and Newcastle disease viruses. Methodology: Two formulations of bivalent vaccines for avian influenza and Newcastle disease viruses were prepared based on the use of IMS1313-nanoparticles (mucosal vaccine) and Montanide ISA71 (parental vaccine) adjuvants. The prepared vaccines were delivered in specific pathogen free (SPF) chickens with different vaccination protocols. Cell mediated and humoral immune response (cytokine expression levels including IFN-γ and IL-6, lymphocyte proliferation, antibodies titers against both H5N1 and NDV) were measured. Challenge trial was carried out to determine the protection percent and shedding pattern of the challenged viruses. Results: Results of the present study revealed a significant increase of IFN-γ and IL-6 genes expression and lymphocytes proliferation in the vaccinated groups compared to the unvaccinated group. Two applications of the mucosal vaccine demonstrated higher hemagglutination inhibition (HI) titers and protection percentage ranged from 40-50% with different levels of virus shedding as measured by qRT-PCR assay. However, when the vaccines were applied in a prime-boost protocol (mucosal-parental, respectively), protection reached 90 and 100% against avian influenza virus (AIV) and Newcastle disease virus (NDV), respectively. No shedding of the NDV-challenge virus was detected whereas, AIV-challenge virus was detected in the samples of the 3rd day post-challenge. Conclusion: Indeed, the use of mucosal-parental vaccines in a prime-boost vaccination protocol demonstrated the potentiality of such approach.

AB - Background and Objective: Avian influenza and Newcastle disease viruses are a continuous threat to poultry industry. Vaccines are increasingly used to control these viral infections. This study aimed to develop efficacious vaccines and vaccination strategies against avian influenza and Newcastle disease viruses. Methodology: Two formulations of bivalent vaccines for avian influenza and Newcastle disease viruses were prepared based on the use of IMS1313-nanoparticles (mucosal vaccine) and Montanide ISA71 (parental vaccine) adjuvants. The prepared vaccines were delivered in specific pathogen free (SPF) chickens with different vaccination protocols. Cell mediated and humoral immune response (cytokine expression levels including IFN-γ and IL-6, lymphocyte proliferation, antibodies titers against both H5N1 and NDV) were measured. Challenge trial was carried out to determine the protection percent and shedding pattern of the challenged viruses. Results: Results of the present study revealed a significant increase of IFN-γ and IL-6 genes expression and lymphocytes proliferation in the vaccinated groups compared to the unvaccinated group. Two applications of the mucosal vaccine demonstrated higher hemagglutination inhibition (HI) titers and protection percentage ranged from 40-50% with different levels of virus shedding as measured by qRT-PCR assay. However, when the vaccines were applied in a prime-boost protocol (mucosal-parental, respectively), protection reached 90 and 100% against avian influenza virus (AIV) and Newcastle disease virus (NDV), respectively. No shedding of the NDV-challenge virus was detected whereas, AIV-challenge virus was detected in the samples of the 3rd day post-challenge. Conclusion: Indeed, the use of mucosal-parental vaccines in a prime-boost vaccination protocol demonstrated the potentiality of such approach.

KW - Avian influenza virus

KW - H5N1

KW - IMS1313-nanoparticles

KW - ISA71

KW - NDV genotype VIId

KW - Newcastle disease virus

KW - Poultry industry

UR - http://www.scopus.com/inward/record.url?scp=85046820652&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046820652&partnerID=8YFLogxK

U2 - 10.3923/ijps.2018.167.174

DO - 10.3923/ijps.2018.167.174

M3 - Article

VL - 17

SP - 167

EP - 174

JO - International Journal of Poultry Science

JF - International Journal of Poultry Science

SN - 1682-8356

IS - 4

ER -